Risk factor
Very high price volatility
Profitability factor
Very weak growth
About
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Buy
Sell